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Background: Paradoxically, beneficial effects of overweight and obesity on survival have been found in patients
after cardiovascular events such as acute myocardial infarction (AMI). This obesity paradox has not been analyzed in
AMI patients with diabetes even though their cardiovascular morbidity and mortality is increased compared to their
counterparts without diabetes. Therefore, the objective of this long-term study was to analyze the association
between body mass index (BMI) and all-cause mortality in AMI patients with and without diabetes mellitus.
Methods: Included in the study were 1190 patients with and 2864 patients without diabetes, aged 28-74 years,
recruited from a German population-based AMI registry. Patients were consecutively hospitalized between 1 January
2000 and 31 December 2008 with a first ever AMI and followed up until December 2011. Data collection comprised
standardized interviews and chart reviews. To assess the association between BMI and long-term mortality from all
causes, Cox proportional hazards models were calculated adjusted for risk factors, co-morbidities, clinical characteris-
tics, in-hospital complications as well as medical and drug treatment.
Results: AMI patients of normal weight (BMI 18.5-24.9 kg/m2) had the highest long-term mortality rate both in
patients with and without diabetes with 50 deaths per 1000 person years and 26 deaths per 1000 person years,
respectively. After adjusting for a selection of covariates, a significant, protective effect of overweight and obesity
on all-cause mortality was found in AMI patients without diabetes (overweight: hazard ratio (HR) 0.73, 95%
confidence interval (CI) 0.58-0.93; p=0.009; obesity: HR 0.64, 95% CI 0.47-0.87; p=0.004). In contrast, an obesity
paradox was not found in AMI patients with diabetes. However, stratified analyses showed survival benefits in
overweight AMI patients with diabetes who had been prescribed statins prior to AMI (HR 0.51, 95% CI 0.29-0.89,
p=0.018) or four evidence-based medications at hospital-discharge (HR 0.52, 95% CI 0.34-0.80, p=0.003).
Conclusion: In contrast to AMI patients without diabetes, AMI patients with diabetes do not experience a survival
benefit from an elevated BMI. To investigate the underlying reasons for these findings, further studies stratifying
their samples by diabetes status are needed.
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An elevated body mass index (BMI) is an independent risk
factor for increased all-cause mortality in the general
population [1]. Furthermore, overweight and obese people
are more likely to be affected by cardiovascular events
than people of normal weight [2]. However, a controversial
survival benefit after cardiovascular events, such as acute
myocardial infarction (AMI), has been detected in over-
weight and obese people [3-8].
Besides excess body weight, diabetes mellitus is a strong
risk factor for cardiovascular morbidity and mortality
[9,10]. People with diabetes have a significantly increased
cardiovascular mortality risk that is even further elevated
after an established cardiovascular event [10-12], such as
AMI [13]. Furthermore, they show worse short- and long-
term outcomes after cardiovascular interventions [14,15]
in comparison with people without diabetes. However,
only a few studies have examined the association between
BMI and long-term mortality after a cardiovascular event
separately for patients with and without diabetes and
showed inconsistent results [16-18].
Thus, the nature of the obesity paradox in AMI patients
cannot be explained thoroughly so far. Additionally, long-
term studies controlling for important comorbidities,
treatment prior and post AMI as well as in-hospital com-
plications have not been conducted on this topic yet.
Therefore, the objective of this long-term observational
study was to analyze the association between BMI and all-
cause mortality in patients with and without diabetes
using data from an established German myocardial infarc-
tion registry and adjusting for a number of relevant risk
factors, co-morbidities, clinical characteristics and in-
hospital complications as well as treatment measures.
Methods
As part of the World Health Organization (WHO) project
MONICA (Monitoring Trends and Determinants in Car-
diovascular disease) the population-based Augsburg Myo-
cardial Infarction (MI) Registry was established in 1984.
MONICA was terminated in 1995 and the registry became
part of the KORA (Cooperative Health Research in the
Region of Augsburg) framework. Since the registry com-
menced, all cases of coronary death and non-fatal AMI
cases of the 25- to 74-year old study population in the city
of Augsburg and the two adjacent counties (about 600,000
inhabitants) have been continuously registered. Patients
admitted to one of the eight hospitals in the study area
and two adjacent counties are included. Methods of case
identification, diagnostic classification of events as well as
data quality control have been described in detail else-
where [19,20]. Data collection and follow-up question-
naires of the MONICA/KORA MI registry have been
approved by the ethics committee of the Bavarian Medical
Association (Bayerische Landesärztekammer) and havebeen performed in accordance with the Declaration of
Helsinki. All study participants gave written informed
consent.
Study population
This study includes all patients consecutively registered be-
tween 1 January 2000 and 31 December 2008, who reached
the hospital alive and whose survival time exceeded 28 days
after AMI. Patients were followed up until December 2011.
The data set comprised 5057 patients with a non-fatal first
ever AMI aged 28-74 years. Patients with missing data on
BMI, diabetes and smoking (n=649) were excluded as well
as patients with incomplete data on any of the relevant co-
variates (n=329). Furthermore, patients who were under-
weight (BMI < 18.5 kg/m2) were not included. The final data
set comprised 4054 patients.
Patients excluded from the study sample had a signifi-
cantly higher crude hazard ratio (HR) for long-term
mortality (HR 2.47, 95% confidence interval (CI) 2.17-
2.82; p < 0.001) compared with included patients.
Data collection
Trained study nurses interviewed the study participants
during their hospital stay using a standardized questionnaire.
The interviews covered demographic information, risk
factors, medications prescribed prior to AMI, and co-
morbidities. Information on AMI characteristics, medical
and drug treatment and in-hospital complications were de-
termined by chart review.
BMI was selected as the index to measure and classify
normal weight, overweight and obesity. It was determined
by assessment of weight and height during hospital stay
and calculated for each patient by dividing the weight (in
kilograms) by the square of the height (in meters). Accord-
ing to the WHO, patients are classified as normal weight if
their BMI lies between 18.5 and 24.9 kg/m2. Overweight
patients have a BMI between 25.0 and 29.9 kg/m2 and the
BMI of obese patients is 30.0 kg/m2 or higher [21].
Whether patients were suffering from diabetes melli-
tus was determined by asking the patients if they had
been previously diagnosed with the disease (yes/no). In
addition, the information provided by the patients was
confirmed by chart review.
Since 2004 a combination of the following four evidence-
based medications (EBMs) is considered the standard of
care after AMI: anti-platelet agents, beta-blockers, angioten-
sin-converting enzyme inhibitors (ACEIs) or angiotensin-re-
ceptor blockers (ARBs) respectively, as well as statins [22].
Since in-hospital complications, such as cardiogenic shock,
occurred infrequently, a variable summarizing the data on
all complications available in the data set (cardiac arrest,
pulmonary edema, bradycardia, re-infarction, ventricular
tachycardia, ventricular fibrillation, cardiogenic shock) was
created (yes/no).
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study, the vital status of the patients in the study population
was monitored through the population registries in- and
outside the study region until 31 December 2011. The me-
dian follow-up time was 6.0 years (IQR 4.1 years).Data analysis
Categorical variables were expressed as percentages and
continuous variables as mean values with standard devi-
ation (SD). Patients were divided into two groups:
patients with and without diabetes. Within the two
groups, potential covariates were cross-tabulated with
BMI (normal weight, overweight and obesity) as the pri-
mary independent variable. Differences in frequencies
were tested using Chi2 or Fisher’s exact test. To evaluate
age differences among the three BMI groups, a one-way
ANOVA (analysis of variance) was performed. Kaplan-
Meier plots were generated along with bivariate
log-rank tests against survival to test for statistical
significance.
Cox proportional hazards models were used to examine
the association between BMI group and long-term mortal-
ity within the two strata (patients with and without dia-
betes). The proportional hazards assumption (parallel
lines of log (-log(event)) versus log of event times) proved
to be valid for the majority of the variables except for
BMI, age, marital status, education, smoking status, year
of infarction, AMI type and ACEIs/ARBs (medication
prior infarction). Included as time-dependent covariates,
further analyses were made with these variables not com-
plying with the proportional hazards assumption. The re-
sults were either not significant and the interaction terms
were therefore not included in the analyses or the inter-
action terms did not make it into the final regression
models because they were dropped during the process of
backwards selection.
Four Cox proportional hazards regression models were
calculated stratified by diabetes (yes/no). First, a crude
model was calculated to examine the association between
BMI and mortality. Second, a minimal model additionally
including the covariates sex and age was calculated. Fi-
nally, two parsimonious models, one for patients with dia-
betes and one for patients without diabetes, were created
using backward selection. Variables that made a statisti-
cally significant (p < 0.05) contribution were included in
the models. The variables sex and age were forced to stay
in the models. In order to control for potential cohort ef-
fects, we tested whether the year of AMI had an influence
on the association between BMI and mortality in both
groups, but no effects were found.
Multicollinearity among the independent variables was
examined by assessing variance inflation factors (VIF) in
the full model prior to backward selection [23].Interaction effects of sex and age and of BMI group with
AMI treatment-related variables were calculated. Signifi-
cant interaction effects between BMI group and statin
treatment prior to AMI as well as prescription of all four
EBMs at discharge were found in patients with diabetes.
Thus, parsimonious models were separately calculated
stratified by statins as medications prior AMI (yes/no) and
by receiving all four EBMs at discharge (yes/no).
Finally, parsimonious models were calculated for follow-
up periods of one to twelve years in one-year intervals. All
data analyses were performed using SAS software, version
9.2 (SAS Institute).
Results
The study sample consisted of 1190 patients with diabetes
(29.4% of the total population) and 2864 patients without
diabetes (see Table 1). Both among patients with and with-
out diabetes overweight individuals accounted for the high-
est percentages with 43.4% (n=516) and 49.3% (n=1411),
respectively. In both groups normal weight patients were
more likely to have a LVEF < 30%, to receive coronary artery
bypass surgery and less likely to receive PCI or any reperfu-
sion treatment compared with overweight or obese individ-
uals. More patients who were overweight or obese than
patients who were of normal weight have received prior
treatment with ACEIs/ARBs or beta-blockers (only among
patients with diabetes). Discharge medication was more
common in overweight and obese patients in terms of
ACEIs/ARBs, all four EBMs, antiplatelet agents (only in pa-
tients with diabetes) and beta-blockers (only in patients
without diabetes). Further sample characteristics are pre-
sented in Table 1 and Additional file 1.
Overall, patients with diabetes had a higher long-term
mortality rate (40 deaths per 1000 person years; n=273) than
patients without diabetes (21 deaths per 1000 person years;
n=366). With 50 deaths per 1000 person years (n=66) and
26 deaths per 1000 person years (n=135) normal weight in-
dividuals had the highest long-term mortality rate both
among patients with and without diabetes, respectively
(see Table 1). Furthermore, Kaplan–Meier survival curves
demonstrated significant differences in survival between
BMI groups in patients without diabetes (p=0.003); in pa-
tients with diabetes, however, a difference could not be
proven (p=0.177) (see Figure 1).
The unadjusted analyses showed significant protective ef-
fects of overweight and obesity in comparison to normal
weight on long-term mortality among patients without dia-
betes; however the same effects could not be proven in pa-
tients with diabetes (see Table 2). For overweight and obese
patients without diabetes the HRs showed minimal vari-
ation even after adjusting for other covariates in the parsi-
monious models (see Table 2). Overweight patients without
diabetes had a statistically significant 0.73-fold risk of dying
(95% CI 0.58-0.93; p=0.009) and obese patients without
Table 1 Characteristics of patients with and without diabetes sub-divided into BMI groups (N=4054)
Diabetes (n=1190) No Diabetes (n=2864)
Normal weight Overweight Obesity Normal weight Overweight Obesity
BMI 18.5-24.9 kg/m2 BMI 25-29.9 kg/m2 BMI ≥ 30 kg/m2 BMI 18.5-24.9 kg/m2 BMI 25-29.9 kg/m2 BMI ≥ 30 kg/m2
(n=226) (n=516) (n=448) p-value (n=848) (n=1411) (n=605) p-value
Sociodemographic characteristics
Female 65 (28.76) 103 (19.96) 169 (37.72) <0.0001 247 (29.13) 226 (16.02) 157 (25.95) <0.0001
Age [years], mean ± SD 63.81 ± 8.79 62.86 ± 8.47 61.96 ± 8.65 0.0262a 59.55 ± 10.00 59.56 ± 9.72 58.98 ± 10.06 0.4460a
Marriedb 169 (77.17) 390 (77.84) 318 (71.78) 0.0778 602 (72.36) 1084 (77.54) 465 (78.15) 0.0091
Living aloneb 36 (16.44) 80 (15.97) 99 (22.35) 0.0287 164 (19.71) 212 (15.16) 86 (14.45) 0.0072
School education > 9 yearsc 54 (25.84) 92 (19.49) 90 (20.98) 0.1722 242 (30.67) 405 (30.82) 133 (23.29) 0.0023
Risk factors and co-morbidities
Angina pectorisd 52 (23.11) 120 (23.35) 117 (26.29) 0.5028 142 (16.78) 241 (17.10) 124 (20.53) 0.1261
Hypertension 183 (80.97) 448 (86.82) 40.5 (90.40) 0.0026 534 (62.97) 1035 (73.35) 521 (86.12) <0.0001
Hyperlipidemia 145 (64.16) 382 (74.03) 362 (80.80) <0.0001 550 (64.86) 1029 (72.93) 455 (75.21) <0.0001
Stroke 27 (11.95) 51 (9.88) 34 (7.59) 0.1667 43 (5.07) 70 (4.96) 33 (5.45) 0.8981
Smoking
Current smoker 70 (30.97) 144 (27.91) 116 (25.89) 0.6129 403 (47.52) 533 (37.77) 211 (34.88) <0.0001
Ex-smoker 77 (34.07) 199 (38.57) 174 (38.84) 200 (23.58) 470 (33.31) 208 (34.38)
Never smoker 79 (34.96) 173 (33.53) 158 (35.27) 245 (28.89) 408 (28.92) 186 (30.74)
Clinical characteristics
Re-infarction during hospitalization 30 (13.27) 83 (16.09) 74 (16.52) 0.5252 89 (10.28) 145 (10.04) 59 (9.75) 0.8964
AMI typee
ST-segment elevation MI 81 (36.65) 198 (38.98) 155 (35.07) 0.1190 360 (43.37) 531 (38.23) 227 (38.09) 0.1329
Non-ST-segment elevation MI 118 (53.39) 285 (56.10) 256 (57.92) 434 (52.29) 783 (56.37) 339 (56.88)
Bundle branch block 22 (9.95) 25 (4.92) 31 (7.01) 36 (4.34) 75 (5.40) 30 (5.03)
Left ventricular ejection fraction < 30%f 35 (21.88) 46 (12.74) 29 (9.93) 0.0015 72 (12.16) 133 (13.34) 33 (7.82) 0.0126
Diabetes treatmentg
Oral antidiabetic agents 72 (57.60) 182 (63.64) 143 (52.77) 0.0044
Insulin therapy 40 (32.00) 78 (27.27) 76 (28.04)
Both antidiabetic agents and insulin therapy 13 (10.40) 26 (9.09) 52 (19.19)
Long-term mortality 66 (29.20) 111 (21.51) 96 (21.43) 0.0453 135 (15.92) 170 (12.05) 61 (10.08) 0.0023
BMI=Body Mass Index, SD=Standard deviation, MI=Myocardial Infarction, AMI=Acute Myocardial Infarction, ACEIs=Angiotensin-converting enzyme inhibitors, ARBs=Angiotensin receptor blockers.
Data are presented as absolute numbers of patients with percentages in brackets, unless stated otherwise.
Chi2-Tests were performed to obtain p-values, unless stated otherwise.




















Figure 1 Kaplan-Meier curves of 12-year survival for normal weight, overweight and obese patients stratified by diabetes status.
Kaplan-Meier curves for (A) patients with diabetes and (B) patients without diabetes.
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p=0.004) compared with normal weight patients. In both
BMI groups the HRs for patients with diabetes attenuated
when covariates were added into the models, however, they
remained non-significant.
In the parsimonious models VIF were below 2.5 indicat-
ing no relevant multicollinearity among the covariates.
Furthermore, parsimonious models for different observa-
tion times (one to twelve years, in 1-year intervals) were cal-
culated comparing HRs of overweight and obese patients
with and without diabetes (see Additional files 2 and 3). Itcould be shown that in AMI patients without diabetes there
is a significant protective effect of overweight and obesity on
all-cause mortality, which attenuated with increasing obser-
vation time while remaining statistically significant. How-
ever, in AMI with diabetes being overweight or obese did
not result in a survival benefit.
Additionally, parsimonious models were calculated inde-
pendently stratified by intake of statins prior AMI and
number of medications taken at discharge (see Table 3).
The stratified analyses resulted in statistically significant
HRs of 0.51 (95% CI 0.29-0.89; p=0.0180) and 0.52 (95% CI
Table 2 Hazard ratios for mortality associated with elevated body mass index in patients with and without diabetes
No diabetes (n=2864) Diabetes (n=1190)
HR [95% CI] p-value HR [95% CI] p-value
Unadjusted model Normal weight 1.0 1.0
Overweight 0.74 [0.59-0.93] 0.0097 0.76 [0.56-1.02] 0.0707
Obesity 0.62 [0.46-0.85] 0.0023 0.79 [0.58-1.09] 0.1495
Minimal modela Normal weight 1.0 1.0
Overweight 0.72 [0.57-0.90] 0.0040 0.80 [0.59-1.08] 0.1467
Obesity 0.64 [0.47-0.86] 0.0036 0.91 [0.77-1.31] 0.5691
Parsimonious model Normal weight 1.0 1.0
Overweight 0.73 [0.58-0.93]b 0.0087 0.83 [0.61-1.13]c 0.2383
Obesity 0.64 [0.47-0.87]b 0.0043 0.98 [0.71-1.36]c 0.8914
HR=Hazard Ratio, CI=Confidence Interval, BMI=Body Mass Index.
aAdjusted for sex and age.
bAdjusted for sex, age, stroke, smoking, re-infarction, left ventricular ejection fraction (<30% versus ≥30%), any reperfusion treatment (coronary artery bypass
surgery, percutaneous coronary intervention (PCI) or thrombolysis), beta-blockers (medication prior AMI), all four medications at discharge (antiplatelet agents,
beta-blockers, ACEIs/ARBs (Angiotensin-converting enzyme inhibitors/Angiotensin receptor blockers), statins).
cAdjusted for sex, age, hyperlipidemia, re-infarction, any reperfusion treatment, statins (medication prior AMI), all four medications at discharge.
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who received stations prior AMI or all four EBMs at dis-
charge. In contrast, no intake of statins had a beneficial ef-
fect on survival of both overweight and obese patients
without diabetes, whereas receiving less than four medica-
tions at discharge was only beneficial for overweight pa-
tients without diabetes. In turn, obese patients withoutTable 3 Hazard ratios for mortality associated with elevated b
stratified by prescribed medications before and after myocar
N
H
Statins prior AMI Normal weight 1
Overweight 0
Obesity 0
No statins prior AMI Normal weight 1
Overweight 0
Obesity 0
Four medications at dischargec Normal weight 1
Overweight 0
Obesity 0
Less than four medications at discharged Normal weight 1
Overweight 0
Obesity 0
HR=Hazard Ratio, CI=Confidence Interval, AMI=Acute Myocardial Infarction, BMI=Bo
aParsimonious model adjusted for sex, age, stroke, smoking, re-infarction, any reper
intervention (PCI) or thrombolysis), beta-blockers (medication prior AMI), all four me
Angiotensin-converting enzyme inhibitors (ACEIs)/Angiotensin receptor blockers (AR
bParsimonious model adjusted for sex, age, hyperlipidemia, re-infarction, any reperf
cEvidence-based medications (EBMs): Antiplatelet agents, beta-blockers, ACEIs/ARBs
dEither antiplatelet agents, beta-blockers, ACEIs/ARBs, statins or a combination of tw
eParsimonious model adjusted for sex, age, stroke, smoking, re-infarction, any reper
fraction (<30% versus ≥ 30%).
fParsimonious model adjusted for sex, age, hyperlipidemia, re-infarction, any reperfudiabetes profited from receiving four medications at
discharge.
Discussion
In this population-based study we could show that an el-
evated BMI in AMI patients had significant effects on
long-term survival in AMI patients without diabetes. Inody mass index in patients with and without diabetes
dial infarction
o diabetes (n=2864) Diabetes (n=1190)
R [95% CI] p-value HR [95% CI] p-value
.0 1.0
.81 [0.44-1.52]a 0.5179 0.51 [0.29-0.89]b 0.0180
.59 [0.26-1.35]a 0.2115 0.82 [0.46-1.47]b 0.5102
.0 1.0
.71 [0.55-0.92]a 0.0082 1.04 [0.71-1.52]b 0.8456
.66 [0.47-0.92]a 0.0131 1.09 [0.73-1.64]b 0.6697
.0 1.0
.76 [0.56-1.03]e 0.0805 0.52 [0.34-0.80]f 0.0027
.56 [0.37-0.86]e 0.0072 0.82 [0.54-1.26]f 0.3745
.0 1.0
.67 [0.47-0.95]e 0.0260 1.21 [0.71-1.89]f 0.4095
.70 [0.44-1.11]e 0.1320 1.03 [0.62-1.73]f 0.9062
dy Mass Index.
fusion treatment (coronary artery bypass surgery, percutaneous coronary
dications at discharge (antiplatelet agents, beta-blockers,
Bs), statins), left ventricular ejection fraction (<30% versus ≥ 30%).
usion treatment, all four medications at discharge.
, statins.
o or three of these medications.
fusion treatment, beta-blockers (medication prior AMI), left ventricular ejection
sion treatment, statins (medication prior AMI).
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tients with diabetes. Interestingly, being prescribed sta-
tins prior AMI or four EBMs at hospital-discharge,
overweight patients with diabetes appeared to have a sig-
nificant survival benefit. Furthermore, in patients with-
out diabetes the detected survival benefit of overweight
and obesity attenuated with increasing observation time.
In line with our findings, Adamopoulos et al. [18] reported
the absence of an obesity paradox among patients with dia-
betes and chronic heart failure. However, differences in
study design and the fact that only two BMI groups (obese
versus non-obese) were compared resulted in limited com-
parability to our study. Contrary to our findings, two studies
showed that normal weight patients with diabetes and pre-
existing cardiovascular events had the highest all-cause mor-
tality rates compared to obese and overweight patients
[16,17]. In addition, a study conducted in Japan compared
30-day survival rates following AMI of overweight (BMI ≥
25 kg/m2) and normal weight (BMI < 25 kg/m2) patients
with diabetes and found a significantly increased risk of
dying among normal weight patients [24]. These contrasting
results could derive from the very limited statistical power
of the study as well as differences in study design. It has
been shown that it can be misleading if BMI groups cover a
wide range of values, since the association of BMI and mor-
tality tends to follow a U- or J-shaped curve instead of in-
creasing monotonically [25,26].
Our findings in patients without diabetes are in line
with results of previous studies on patients with AMI
[3-8,24,27-29] as well as recent systematic reviews in-
cluding studies on patients with cardiovascular disease
[30-32]. However, only one study has analyzed AMI pa-
tients without diabetes separately [18].
Interestingly, stratified analyses revealed a significant
survival benefit in overweight patients with diabetes who
were being prescribed statins prior AMI as well as in over-
weight patients with diabetes who received all four EBMs
at hospital discharge. One study concluded that a statin
therapy in patients with diabetes and without previous
CVD might have a beneficial effect on survival [33] and
other studies have shown that prescribing all four EBMs at
hospital discharge resulted in a significant reduction in
long-term morbidity and mortality [22,34]. It has been also
demonstrated that medications prescribed to treat hyper-
tension (beta-blockers, ACEIs, ARBs) and elevated choles-
terol levels (statins) exert pleiotropic effects on myocardial
remodeling and mortality after a cardiovascular event such
as AMI [34].
In our study, the survival benefit of overweight and
obese patients without diabetes attenuated with increasing
observation time. Therefore, previous studies focusing on
short-term mortality might have overestimated the pro-
tective effect of overweight and obesity on survival after
AMI. The paradoxically protective effect could only bevalid over a short period of time [35] and the fact that it
attenuated with increasing observation time in our ana-
lysis could be a result of patients’ weight loss [17] or due
to overweight and obese patients being more robust to-
wards acute cardiovascular events.
Several factors could have caused the discrepancy in
long-term survival in patients with and without diabetes:
First, it can be hypothesized that an obesity paradox did
not occur in patients with diabetes due to adverse effects
of the disease or additional co-morbidities [36]. Com-
bined with excess body weight they might be even more
fatal. It has been shown that being overweight or obese
does not exclude the possibility of being in a better car-
diometabolic shape than normal weight patients [37]. A
recent study demonstrated that normal weight patients
with cardiometabolic dysfunction are at similar or even
higher risk of cardiovascular morbidity and all-cause
mortality in comparison with overweight and obese pa-
tients with cardiometabolic dysfunction [38]. However,
in another study in patients with non-ST-segment eleva-
tion acute coronary syndrome only two components of
the metabolic syndrome (low high-density lipoprotein
and high triglycerides) were associated with higher 1-
year mortality when examined separately [39]. Further-
more, it has been suggested to differentiate between
metabolically healthy and metabolically obese patients
within the BMI groups to better understand the effects
of metabolic syndrome [37]. The cardiometabolic bur-
den of adiposity, certain components of the metabolic
syndrome and additional comorbidities might therefore
play an important role in the explanation of the obesity
paradox [37,38,40].
Second, we were not able to consider the time of dia-
betes diagnosis, the quality or stage of diabetes treatment
as well as information on the treatment of overweight or
obesity prior AMI. Previous studies revealed that the time
of diabetes diagnosis might be relevant [41].
Third, additional comorbidities, such as cancer, changes
in BMI as a result of weight gain or loss as well as adher-
ence to prescribed medication after hospital discharge
were not considered in our study. Recent findings indicate
that BMI changes have an impact on long-term cardiovas-
cular mortality [42].
Finally, there is evidence suggesting that the existence of
an obesity paradox highly depends on the indices used to
measure and classify normal weight, overweight and obesity
[16,43,44]. Previous studies have shown that BMI combined
with indices measuring the distribution of body-fat, such as
waist-hip-ratio (WHR) or waist circumference (WC), offer
more reliable results regarding mortality after cardiovascular
events [16,45,46]. Especially in the context of CVDs, abdom-
inal obesity is associated with a significantly increased mor-
tality risk [47]. However, besides a higher adipose mass,
overweight and obesity can be accompanied by an increase
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diometabolic perspective and could positively influence sur-
vival after cardiovascular events [8,37]. Moreover, abdominal
obesity can also occur in normal weight people, which might
increase their risk for cardiovascular events [37]. Using indi-
ces that better discriminate between fat and lean mass and
that measure the distribution of body fat could help to shed
light on this matter.
To our knowledge this is the first study investigating the
association between BMI and long-term mortality in AMI
patients that distinguished between patients with and with-
out diabetes. This study has further strengths. First, import-
ant covariates such as medication prior and post AMI, in-
hospital treatment and complications as well as a selection
of comorbidities, were included. Second, we were able to
examine the impact of diabetes and BMI on mortality over
a longer period of time than any other study in this field be-
fore. Third, excluding patients with a BMI < 18.5 kg/m2
ensured that patients with possible cachexia caused by
other diseases, such as cancer, were not included in our
sample. Fourth, data were collected in the framework of
a population-based registry with consecutive enrollment.
This approach ensured that all patients with an AMI within
the study area, who reached the hospital alive and survived
longer than 28 days, were included in the sample. Finally,
in contrast to other studies, patients were considered to
suffer from diabetes if their condition was confirmed by
chart-review.
Potential limitations of this study should be taken into
account. Changes in body weight during the long follow-
up period could not be considered. Patients older than
74 years were not included in our study. Due to a con-
siderable number of patients who died before reaching
the hospital or in the course of 28 days we cannot ex-
clude possible bias of our results. Information on other
relevant conditions affecting survival after AMI, such as
any malignant disease and impaired renal function were
not collected in this study. The proportion of patients
with type-1-diabetes only accounted for 2.1% of the
study population with diabetes mellitus (data not
shown). We therefore believe that the potential bias lies
within tolerable limits. Finally, no data was available on
the duration of therapy or treatment prior and post AMI
as well as on the patients’ compliance with taking pre-
scribed medication before and after AMI had occurred.
Conclusion
In AMI patients without diabetes we detected a significant
protective effect of overweight and obesity on all-cause
mortality, which attenuated with increasing observation
time while remaining statistically significant. However, in
AMI patients with diabetes being overweight or obese did
not result in a survival benefit. Surprisingly, a paradoxical
association was found in overweight AMI patients withdiabetes who had received statins prior AMI and who had
been prescribed with four EBMs at hospital discharge.
In order to thoroughly investigate the association be-
tween BMI and all-cause mortality in patients with and
without diabetes further studies are needed.
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